MX2022002554A - Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). - Google Patents

Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).

Info

Publication number
MX2022002554A
MX2022002554A MX2022002554A MX2022002554A MX2022002554A MX 2022002554 A MX2022002554 A MX 2022002554A MX 2022002554 A MX2022002554 A MX 2022002554A MX 2022002554 A MX2022002554 A MX 2022002554A MX 2022002554 A MX2022002554 A MX 2022002554A
Authority
MX
Mexico
Prior art keywords
compounds
hexapyrido
oxazin
magl inhibitors
magl
Prior art date
Application number
MX2022002554A
Other languages
English (en)
Inventor
Uwe Grether
Benoit Hornsperger
Bernd Kuhn
Hans Richter
Fionn O'hara
Carsten Kroll
Marius Daniel Rinaldo Lutz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022002554A publication Critical patent/MX2022002554A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) en donde A, B, L, X, R1, R2, R3 y R4 son como se describen en la presente, composiciones que incluyen los compuestos, procesos para manufacturar los compuestos y métodos para usar los compuestos como inhibidores de la monoacilglicerol lipasa (MAGL). (ver Fórmula).
MX2022002554A 2019-09-09 2020-09-07 Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). MX2022002554A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19196089 2019-09-09
PCT/EP2020/074897 WO2021048036A1 (en) 2019-09-09 2020-09-07 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Publications (1)

Publication Number Publication Date
MX2022002554A true MX2022002554A (es) 2022-03-22

Family

ID=67902336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002554A MX2022002554A (es) 2019-09-09 2020-09-07 Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).

Country Status (17)

Country Link
US (2) US20210094971A1 (es)
EP (1) EP4028401B1 (es)
JP (1) JP2022546853A (es)
KR (1) KR20220061119A (es)
CN (1) CN114364682A (es)
AR (1) AR119910A1 (es)
AU (1) AU2020344921A1 (es)
BR (1) BR112022003704A2 (es)
CA (1) CA3151218A1 (es)
CL (1) CL2022000551A1 (es)
CO (1) CO2022002339A2 (es)
CR (1) CR20220091A (es)
IL (1) IL289233A (es)
MX (1) MX2022002554A (es)
PE (1) PE20220904A1 (es)
TW (1) TW202124392A (es)
WO (1) WO2021048036A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
CN111386269A (zh) 2017-11-28 2020-07-07 豪夫迈·罗氏有限公司 新型杂环化合物
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
MX2021001433A (es) 2018-08-13 2021-04-12 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos
WO2024071398A1 (ja) * 2022-09-30 2024-04-04 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニスト

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
EP3298003B1 (en) 2015-05-21 2023-04-19 GlaxoSmithKline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
WO2017087863A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10385057B2 (en) * 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
CN111566105A (zh) * 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
DK3768684T3 (da) * 2018-03-22 2023-04-24 Hoffmann La Roche Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere
SG11202012222TA (en) * 2018-08-13 2021-01-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
MX2021001433A (es) * 2018-08-13 2021-04-12 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
PE20211870A1 (es) * 2018-11-22 2021-09-21 Hoffmann La Roche Nuevos compuestos heterociclicos

Also Published As

Publication number Publication date
EP4028401A1 (en) 2022-07-20
EP4028401B1 (en) 2023-11-22
US20220275005A1 (en) 2022-09-01
WO2021048036A1 (en) 2021-03-18
CO2022002339A2 (es) 2022-03-08
IL289233A (en) 2022-02-01
CL2022000551A1 (es) 2022-11-18
EP4028401C0 (en) 2023-11-22
JP2022546853A (ja) 2022-11-09
CA3151218A1 (en) 2021-03-18
BR112022003704A2 (pt) 2022-05-24
PE20220904A1 (es) 2022-05-30
KR20220061119A (ko) 2022-05-12
US20210094971A1 (en) 2021-04-01
AR119910A1 (es) 2022-01-19
AU2020344921A1 (en) 2022-02-17
TW202124392A (zh) 2021-07-01
CN114364682A (zh) 2022-04-15
CR20220091A (es) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2022002554A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
CR20200416A (es) Nuevos compuestos heterocíclicos
MX2022002311A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
PH12021551167A1 (en) New heterocyclic compounds
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
CR20220116A (es) Compuestos heterocíclicos
BR112015023397A2 (pt) benzoxazois substituídos e métodos de uso dos mesmos
MX2022002831A (es) Compuestos heterociclicos.
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
CR20220004A (es) Nuevos compuestos heterocíclicos
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
CR20210530A (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
MX2023002224A (es) Compuestos heterociclicos.
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
MX2021001565A (es) Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad).
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2022011708A (es) Derivados de benzodiazepinas como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a gamma1.
MX2021002087A (es) Derivados de heteroarilo biciclicos.